Taken together, these results demonstrate that the reduction in TDP-43 levels by the injection of gapmer ASO 15 leads to sustained improvement of the abnormal phenotypes of hTDP-43 mice that are caused by the expression of human TDP-43 with an A315T mutation, including anxiety-like behavior and the progressive decline in locomotor function. The gene discussed is TARDBP; the disease is Anxiety.